Physician profile
Brian Basco
NPI 1871156042
$5,507.59
in general payments reported to CMS, 2019-2025
52 companies · $2,666 in 2025
The $2,666 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.17 · 2020: $17.06 · 2021: $263 · 2022: $481 · 2023: $949 · 2024: $1,081 · 2025: $2,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.75 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $630.85 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $447.33 | 2024-2025 | |
| Pfizer INC. | $381.35 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $368.03 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $265.97 | 2021-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $261.10 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $242.38 | 2023-2025 | Hyqvia |
| Abbott Laboratories | $238.54 | 2023 | Proclaim |
| Vanda Pharmaceuticals INC. | $205.08 | 2024-2025 | Ponvory |
| Lundbeck LLC | $190.17 | 2024-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $177.05 | 2021-2024 | |
| Neurelis, INC. | $174.57 | 2021-2025 | Valtoco |
| Emd Serono, INC. | $173.98 | 2024-2025 | |
| Biogen, INC. | $169.57 | 2023-2025 | Vumerity, Leqembi, Tysabri |
| Otsuka America Pharmaceutical, INC. | $152.59 | 2023-2025 | Rexulti, Nuedexta |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Basco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.